Erfahrene Führungspersönlichkeit bringt starke Erfolgsbilanz in der kommerziellen Expansion in den USA mit Das Unternehmen konzentriert sich darauf, die Markteinführung von Phagenyx® zu beschleunigen, um mehr Patienten in den USA und Europa behandeln zu können Phagenyx® ist die erste Therapie ihrer Art, die Neurostimulation zur Wiederherstellung der Schluckkontrolle bei Patienten…
Accomplished leader brings strong track record of commercial expansion in the US Company is focused on accelerating uptake of Phagenyx® to treat more patients in the US and Europe Phagenyx® is a first-of-its-kind therapy using neurostimulation to restore swallowing control in patients with severe swallowing difficulties (dysphagia) MANCHESTER, England, Sept.…
Phagenesis, ein Medizintechnikunternehmen, das sich auf die Behandlung von Schluckstörungen spezialisiert hat, schließt erfolgreich eine Finanzierungsrunde der Serie D über 42 Millionen USD unter der Leitung von EQT Life Sciences und Sectoral Asset Management ab. Manchester, Vereinigtes Königreich – 4. März 2024 – Das britische Pionierunternehmen Phagenesis hat ein revolutionäres…
Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management. Manchester, UK – March 4, 2024 – Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat…
Hospital is one of the first three facilities in the country using the Phagenyx™ Neurostimulation System PHOENIX (Aug. 15, 2023) – 55-year-old Michael John Coe of Prescott Valley never thought much about his ability to swallow until he was forced to re-learn this essential function after suffering three strokes recently.…
Augusta University Health’s Stroke Center was the first in Georgia to be designated as an Advanced Comprehensive Stroke Center a decade ago, and it is making history again as the first acute care medical center in the country to offer an innovative treatment for patients with dysphagia. Dysphagia is the…
NEWS PROVIDED BY Gaylord Specialty Healthcare 09 May, 2023, 15:45 ET WALLINGFORD, Conn., May 9, 2023 /PRNewswire/ — Gaylord Specialty Healthcare, a nonprofit rehabilitation-focused healthcare system, is proud to announce that it is the first healthcare organization in the nation to use the Phagenyx® Neurostimulation System from Phagenesis, Ltd. to treat…
Phagenesis Launches Phagenyx Neurostimulation System in the U.S. NEWS PROVIDED BY Phagenesis, Ltd Oct 10, 2022, 02:00 ET MANCHESTER, England, Oct. 10, 2022 /PRNewswire/ — Phagenesis Ltd, today announced that the U.S. Food and Drug Administration (FDA) has granted a De Novo request for the Phagenyx® Neurostimulation System, a first-of-its-kind…
MedTech Innovator Announces Top 50 Startups Selected for the 2022 Cohort in Tenth Year of World’s Largest MedTech Accelerator Program 2022 Cohort Includes Medical Device, Diagnostics and Digital Health Startups From Across the Globe Developing Innovative Technologies to Improve Patient Care and Outcomes June 07, 2022 08:00 AM Eastern Daylight…
Rapid Swallow Improvement Following Pharyngeal Electrical Stimulation In a COVID-19 Patient With Long-Term Severe Neurogenic Dysphagia: A Case Report
Pharyngeal electrical stimulation helps critically ill COVID-19 patients with dysphagia recover safely: a case report using the Phagenyx® PES System
Largest real-world study of Phagenyx® demonstrates significant benefits of treatment in patients with unsafe swallowing (neurogenic dysphagia) resulting from multiple causes
Phagenesis Receives FDA Breakthrough Designation For Its Phagenyx® System FDA’s Breakthrough Device Designation Program allows for priority review of the Phagenyx® System
Multicentre randomised controlled trial confirms the significant benefits of Phagenyx® treatment for tracheostomised stroke patients with dysphagia